Wolfgang Sippl Selected Research

Histone Deacetylases (Histone Deacetylase)

4/2022	Docking, Binding Free Energy Calculations and In Vitro Characterization of Pyrazine Linked 2-Aminobenzamides as Novel Class I Histone Deacetylase (HDAC) Inhibitors.
1/2022	Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis.
1/2022	First Fluorescent Acetylspermidine Deacetylation Assay for HDAC10 Identifies Selective Inhibitors with Cellular Target Engagement.
1/2022	Development of New Inhibitors of HDAC1-3 Enzymes Aided by In Silico Design Strategies.
12/2021	Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity.
1/2021	The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs.
1/2021	Strategies To Design Selective Histone Deacetylase Inhibitors.
10/2020	Histone deacetylases inhibitors as new potential drugs against Leishmania braziliensis, the main causative agent of new world tegumentary leishmaniasis.
7/2020	Natural Products as Modulators of Sirtuins.
2/2018	Identification of Bichalcones as Sirtuin Inhibitors by Virtual Screening and In Vitro Testing.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wolfgang Sippl Research Topics

Disease

61	Neoplasms (Cancer) 04/2022 - 05/2007
9	Schistosomiasis (Bilharziasis) 01/2022 - 01/2013
8	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2018 - 01/2008
7	Parasitic Diseases (Parasitic Disease) 01/2022 - 07/2015
5	Malaria 01/2018 - 12/2013
4	Neglected Diseases 01/2022 - 01/2013
4	Breast Neoplasms (Breast Cancer) 01/2022 - 03/2008
4	Neuroblastoma 01/2022 - 12/2017
4	Alzheimer Disease (Alzheimer's Disease) 05/2021 - 09/2018
4	Prostatic Neoplasms (Prostate Cancer) 01/2018 - 01/2012
3	Infections 01/2022 - 02/2014
3	Carcinogenesis 01/2020 - 07/2015
3	Neoplasm Metastasis (Metastasis) 01/2020 - 04/2014
3	Inflammation (Inflammations) 02/2016 - 02/2015
2	Leukemia 01/2022 - 01/2009
2	Leishmaniasis 10/2020 - 01/2017
2	Cardiovascular Diseases (Cardiovascular Disease) 10/2019 - 12/2011
2	Nervous System Diseases (Neurological Disorders) 01/2018 - 01/2017
2	Trypanosomiasis 01/2017 - 10/2007
2	Tuberculosis (Tuberculoses) 02/2014 - 01/2014
2	Metabolic Diseases (Metabolic Disease) 12/2012 - 01/2008
2	Pathologic Processes 11/2010 - 10/2010
1	Cysticercosis 01/2022
1	Echinococcosis (Hydatid Cysts) 01/2022
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022
1	Edema (Dropsy) 08/2021
1	Diabetic Nephropathies (Diabetic Nephropathy) 04/2021
1	COVID-19 01/2021
1	Parkinson Disease (Parkinson's Disease) 07/2020
1	Shock 01/2020
1	Huntington Disease (Huntington's Disease) 01/2020
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2020
1	Hypoxia (Hypoxemia) 01/2019
1	Medulloblastoma 01/2018
1	Toxoplasmosis 01/2017
1	Myoglobinuria 04/2016

Drug/Important Bio-Agent (IBA)

28	Pharmaceutical PreparationsIBA 01/2022 - 05/2011
17	Histone Deacetylases (Histone Deacetylase)IBA 04/2022 - 07/2015
12	SirtuinsIBA 01/2022 - 01/2008
11	EnzymesIBA 01/2022 - 03/2008
11	Histones (Histone)IBA 04/2021 - 05/2007
10	Proteins (Proteins, Gene)FDA Link 05/2021 - 01/2009
9	Histone Deacetylase InhibitorsIBA 01/2022 - 02/2009
6	Praziquantel (Biltricide)FDA Link 01/2022 - 01/2013
5	Lysine (L-Lysine)FDA Link 01/2022 - 09/2013
5	Biological ProductsIBA 05/2021 - 03/2008
5	Phosphotransferases (Kinase)IBA 12/2017 - 01/2014
4	TubulinIBA 08/2020 - 03/2008
4	Hormones (Hormone)IBA 09/2013 - 08/2007
3	Sirtuin 2IBA 02/2016 - 02/2015
2	ZincIBA 01/2022 - 01/2016
2	VaccinesIBA 10/2020 - 12/2013
2	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 05/2011
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2018 - 01/2017
2	Protein Kinase InhibitorsIBA 12/2017 - 04/2014
2	Transcription Factors (Transcription Factor)IBA 01/2016 - 07/2015
2	Histone DemethylasesIBA 01/2016 - 12/2012
2	AndrogensIBA 09/2013 - 01/2012
2	Histone MethyltransferasesIBA 12/2012 - 01/2009
1	Tyrosine (L-Tyrosine)FDA Link 01/2022
1	entinostat (MS 275)IBA 01/2022
1	AnthelminticsIBA 01/2022
1	CarbamatesIBA 01/2022
1	CarrageenanIBA 08/2021
1	Indomethacin (Indometacin)FDA LinkGeneric 08/2021
1	ChromatinIBA 05/2021
1	AmidesIBA 05/2021
1	LigandsIBA 05/2021
1	Glucose (Dextrose)FDA LinkGeneric 04/2021
1	ellagitanninIBA 08/2020
1	TriazolesIBA 01/2020
1	Sirtuin 1IBA 01/2020
1	6- chloro- 2,3,4,9- tetrahydro- 1H- carbazole- 1- carboxamideIBA 01/2020
1	ElastinIBA 10/2019
1	Peptides (Polypeptides)IBA 10/2019
1	Prolyl Hydroxylases (Prolyl Hydroxylase)IBA 01/2019
1	Deferasirox FDA Link 01/2019
1	PCI 34051IBA 12/2018
1	Messenger RNA (mRNA)IBA 12/2018
1	CrizotinibIBA 12/2018
1	cinnamic acidIBA 10/2018
1	NAD (NADH)IBA 02/2018
1	Oxidoreductases (Dehydrogenase)IBA 01/2018
1	Flavin-Adenine Dinucleotide (FAD)IBA 01/2018
1	Monoamine Oxidase (MAO)IBA 01/2018
1	Antineoplastic Agents (Antineoplastics)IBA 01/2018
1	Differentiation AntigensIBA 01/2018
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2018
1	CaspasesIBA 01/2018
1	Somatomedin Receptors (Somatomedin Receptor)IBA 12/2017
1	tyrosine receptor (receptor, tyrosine)IBA 12/2017
1	lissamine rhodamine B (sulforhodamine B)IBA 01/2017
1	N-Methylaspartate (NMDA)IBA 01/2017
1	Antiparasitic Agents (Antiparasitics)IBA 01/2017
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2017
1	Carnitine O-Palmitoyltransferase (Carnitine Palmitoyltransferase II)IBA 04/2016

Therapy/Procedure

15	Therapeutics 01/2022 - 04/2012
2	Drug Therapy (Chemotherapy) 01/2016 - 12/2013
1	Caloric Restriction 01/2018